Year: 2026

Introduction Kenya’s public and private healthcare system continues to face real gaps in oncology drug availability — cancer patients in oncology wards have gone without treatment cycles when specific agents run short at the national level, and many patients end up sourcing cancer medicines themselves due to local stockouts. For hospitals, distributors, and even patients trying to import oncology drugs India manufacturers produce, understanding the legal, safe pathway matters as much as finding a supplier. India is a major global supplier of WHO – Generic medicines, including oncology products, making it an important sourcing market for Kenyan pharmaceutical buyers., making it a natural sourcing destination for Kenyan buyers. Manufacturers like Salvavidas Pharma, based in Surat, India, specialize in oncology and anti-HIV products specifically for export to African markets. This guide covers how that import process actually works — and just as importantly, how to avoid the risks that come with sourcing cancer drugs through unverified channels. Why Kenyan Buyers Look to India for Oncology Drugs Kenya’s cancer drug supply challenges are well documented in oncology wards, patients have missed treatment cycles because drugs such as Goserelin and Rituximab were not procured in tim, part of a broader supply chain crisis affecting multiple hospital-level medicine categories. Separately, patients often import cancer drugs — especially targeted therapies — due to local stockouts or perceived cost concerns, sometimes without verifying the source. India’s generic oncology manufacturing base offers a legitimate alternative, but only when sourced through the proper regulatory channels rather than informal or unverified routes. The Right Way vs. the Risky Way to Import This distinction matters more for oncology drugs than almost any other category, given the direct clinical consequences of substandard product. The risky path: Individual or informal sourcing of cancer drugs without verifying manufacturer credentials, storage conditions, or the product’s PPB registration status. Some oncology medicines require controlled temperature storage and transportation, depending on the individual product’s approved storage conditions. Exporters and buyers should follow the manufacturer’s specified storage and transport requirements throughout the supply chain. — under-dosing or overdosing from compromised product can force patients into additional costs from ineffective treatment or managing severe toxicities. The correct path: Importing through a PPB-registered channel, from a WHO-GMP certified Indian manufacturer, with full documentation and proper temperature-controlled logistics — whether you’re a hospital, distributor, or institutional buyer. What’s Required to Import Oncology Drugs from India to Kenya 1. PPB Product Registration The oncology product must be registered with Kenya’s Pharmacy and Poisons Board before it can be legally imported or distributed — this is non-negotiable regardless of the product’s approval status in India or elsewhere. 2. PPB Import Permit Importers and other regulated entities must meet the applicable PPB licensing and import requirements. Where an import permit is required, the shipment must be supported by the appropriate authorization before importation. 3. Local Authorised Representative (LAR) Indian manufacturers exporting to Kenya typically need a Kenya-based representative or distributor to manage registration and import permit applications on their behalf. 4. Certificate of Pharmaceutical Product (COPP) and GMP Certification Certificate of Pharmaceutical Product (COPP) and GMP CertificationDepending on the product and regulatory pathway, Kenyan registration documentation may require a Certificate of Pharmaceutical Product (COPP) and evidence of compliance with applicable GMP requirements. Indian manufacturers should maintain current regulatory certificates issued by the appropriate authorities. 5. Validated Cold Chain Logistics Temperature-sensitive specialty medicines require validated storage at origin and qualified shipping containers for the transit route, with evidence of Good Distribution Practice maintained across the entire journey expected by PPB and port health authorities. Many oncology drugs fall into this temperature-sensitive category. 6. Named Patient / Emergency Import Route (Where Applicable) Not every clinically needed medicine is registered in Kenya — specialty oncology agents and rare disease treatments sometimes require a named-patient import pathway as an alternative to standard commercial registration, used for individual patient access rather than bulk distribution. How the Process Typically Works Step 1: Identify a WHO-GMP Certified Indian ManufacturerVerify the manufacturer’s certifications and export track record before engaging further. Step 2: Confirm PPB Registration StatusCheck whether the specific oncology product is already PPB-registered, or whether registration needs to be initiated — this affects timeline significantly. Step 3: Engage a Local Authorised RepresentativeRequired to manage the Kenya-side registration and import permit process. Step 4: Apply for the Import Permit The local agent applies for the permit through the PPB portal, and the consignment is declared through the single window system, matched against the import permit before customs release. Step 5: Arrange Validated Cold Chain ShippingCoordinate temperature-controlled logistics appropriate to the specific product’s stability requirements. Step 6: Customs Clearance and Port Health VerificationFinal release requires the import permit, registration documentation, and evidence of maintained cold chain integrity. What to Verify Before Choosing a Supplier ✔ WHO-GMP or equivalent certification on the manufacturing facility ✔ Established export track record, ideally with prior shipments into East Africa specifically ✔ PPB registration status of the exact product and formulation you need ✔ Cold chain capability, verified rather than assumed, for temperature-sensitive oncology products ✔ Transparent documentation — COPP, CoA, and GMP certificates provided without hesitation Conclusion For Kenyan hospitals, distributors, and institutional buyers looking to import oncology drugs India manufacturers produce, the opportunity is real — India’s generic oncology sector offers quality treatment at costs that matter for a healthcare system already under supply pressure. But given the clinical stakes involved, the registered, PPB-compliant import pathway is the only responsible route, not an informal or unverified one. Salvavidas Pharma, a WHO-GMP certified pharmaceutical manufacturer and exporter based in Surat, India, specializes in oncology and anti-HIV products alongside a broader generics portfolio, with established export experience into African markets. Working with an experienced partner like Salvavidas Pharma — one with certified oncology manufacturing, a track record of compliant exports, and validated cold chain logistics — can make this process considerably more reliable for Kenyan buyers navigating real supply gaps.

Introduction For exporters targeting Ghana, the Ghana Essential Medicines List (EML), developed within Ghana’s Ministry of Health framework, is a useful reference point alongside FDA Ghana product registration. While FDA Ghana registration addresses the regulatory requirements for pharmaceutical products entering the market, the EML provides a reference for medicines used within Ghana’s healthcare system, including those considered under the National Health Insurance Scheme (NHIS). This guide covers how Ghana’s EML is structured and what it means for exporters planning market entry. What Is the Ghana Essential Medicines List? Essential medicines are those that satisfy the priority healthcare needs of the population, selected with due regard to public health relevance, evidence on efficacy and safety, and comparative cost-effectiveness. Ghana’s EML is derived from its companion Standard Treatment Guidelines, ensuring harmony between clinical treatment, procurement, and reimbursement decisions. The list uses the Recommended International Non-proprietary Name (rINN) for all medicines, in line with WHO recommendations and practice a detail worth noting for exporters preparing product documentation and labeling for the Ghanaian market. Important distinction for exporters: the EML is separate from FDA Ghana product registration. FDA registration and the accompanying import permit are what legally allow a specific product into Ghana. The EML instead reflects what the public health system is structured to procure, prescribe, and — critically in Ghana’s case — reimburse through NHIS. How Ghana’s EML Is Structured Ghana’s EML has two structural features that distinguish it from Nigeria’s and Kenya’s essential medicines lists, both worth understanding before entering the market. Facility-Level Coding Medicines are grouped by the facility level at which they can be prescribed and dispensed: Level A (Community), Level M (Midwifery), Level B1 (Health Centre without Doctor), Level B2 (Health Centre with Doctor), Level C (District Hospital), Level D (Regional/Teaching Hospital), Level SD (Specialist Drugs), and Level PD (Programme Drugs). Specialist Drugs are restricted to use by qualified specialists, while Programme Drugs are used specifically within Ministry of Health public health programmes and their guidelines. This matters directly for exporters: a product’s facility-level classification affects which type of buyer — community clinic, district hospital, or teaching hospital — will realistically be procuring it. NHIS Reimbursement Status Medicines are also marked as either reimbursed (R) or not reimbursed (NR) by the National Health Insurance Authority, based on the NHIS benefits package. A product’s reimbursement status has a direct effect on procurement volume, since NHIS-reimbursed medicines see substantially higher institutional demand than non-reimbursed equivalents. Key Therapeutic Categories on the EML While the exact category count varies by edition, the EML follows the WHO Model List structure, with categories most relevant to exporters including: 1. Anti-Infective Medicines Antibiotics, antimalarials, and antiviral agents — consistently the highest-volume category given Ghana’s infectious disease burden. 2. Anti-HIV / Antiretroviral Medicines Tied to Ghana’s national HIV treatment program and typically NHIS-reimbursed given their public health priority status. 3. Maternal and Child Health Medicines Includes midwifery-level (Level M) medicines specifically, reflecting Ghana’s facility-level structure for maternal care access. 4. Medicines for Non-Communicable Diseases A growing category as Ghana’s disease burden shifts toward chronic conditions alongside infectious disease. 5. Specialist and Programme Drugs Restricted-use categories (Level SD and PD) covering complex conditions and Ministry of Health public health programmes specifically — relevant for exporters supplying more specialized or programmatic products. Why the EML Matters for Exporters ✔ NHIS reimbursement status affects real demand A product’s R/NR marking has a direct bearing on how much institutional buyers will actually order — worth checking before prioritizing a product for Ghana. ✔ Facility-level coding shapes buyer targeting Understanding whether a product is classified for community, district, or specialist-level use helps target the right distributor and institutional relationships. ✔ rINN naming affects documentation Product naming across FDA registration documents and marketing materials should align with rINN conventions used in the EML. ✔ Distinct from, but complementary to, FDA registration An EML-aligned, NHIS-reimbursed product still requires full FDA Ghana registration and import permit — both processes matter independently. How Exporters Can Use This Information ✔ Check NHIS reimbursement status for target products before prioritizing them for the Ghanaian market✔ Align product naming and documentation with rINN conventions used in Ghana’s EML and Standard Treatment Guidelines✔ Match your product’s facility-level classification to the right type of distributor or institutional buyer relationship✔ Prioritize FDA Ghana registration for products in high-reimbursement, high-priority EML categories Conclusion Ghana’s EML stands out for its facility-level coding and NHIS reimbursement structure — details that directly shape which buyers will procure a given product and at what volume. Exporters who understand this structure, on top of securing FDA Ghana registration and import permits, are better positioned to match their product portfolio to how Ghana’s healthcare system actually buys. Partnering with an experienced pharma export company in India familiar with both FDA Ghana requirements and EML/NHIS structures helps align product strategy with actual market demand rather than guesswork.

Introduction For exporters targeting Kenya’s healthcare market, the Kenya Essential Medicines List (KEML) is a key reference point alongside PPB product registration. Where PPB registration determines whether a specific product can legally enter the market, the KEML provides a reference for medicines prioritized within Kenya’s public health system and Universal Health Coverage (UHC) programs. This guide covers what the KEML is, how it’s structured, and how exporters can use it to align product strategy with real market demand. What Is the Kenya Essential Medicines List (KEML)? Kenya developed its first Essential Medicines List in 1981, making it one of the longer-standing essential medicines programs on the continent. The KEML is a key tool used to promote access to essential medicines, and through correct selection, procurement, and use, to achieve maximum therapeutic benefit and optimize patient outcomes under Universal Health Coverage. The rationale for listing medicines in the KEML is informed by the WHO Model List of Essential Medicines, which countries adapt to their own healthcare needs and context., covering both adult and pediatric formulations, which countries then adapt to their own context. The KEML is reviewed and updated periodically, so exporters should always refer to the latest official edition when assessing product opportunities in Kenya. depending on the extent of accumulated changes needed, with urgent amendments communicated through established coordination channels in the interim. Important distinction for exporters: the KEML is separate from PPB product registration. PPB registration and other applicable regulatory approvals address whether a pharmaceutical product can legally enter the Kenyan market, while the KEML provides guidance on medicines considered essential and prioritized within the healthcare system Key Therapeutic Categories on the KEML The current KEML categorizes medicines into 35 therapeutic groups selected based on public health needs and priorities, with recent editions adding coverage for non-communicable diseases and neglected tropical diseases. The major categories relevant to export planning include: 1. Anti-Infective Medicines The KEML classifies antibiotics using the WHO‘s Access, Watch, Reserve framework, guiding antimicrobial resistance policy a structure exporters should be aware of when positioning antibiotic products. 2. Antimalarials A consistently prioritized category given malaria’s continued burden across much of Kenya. (WHO – Malaria) 3. Anti-HIV / Antiretroviral Medicines Reflecting Kenya’s substantial national HIV treatment program under its UHC framework. 4. Medicines for Non-Communicable Diseases An increasingly important category covering cardiovascular disease, diabetes, and other chronic conditions as non-communicable diseases (NCDs) become a growing public health priority. 5. Medicines for Pain and Palliative Care A distinct, standalone category reflecting growing attention to palliative care access. 6. Anaesthetics and Perioperative Medicines Core hospital-level medicines required across Kenya’s healthcare facility network. 7. Neglected Tropical Disease Medicines A category specifically expanded in recent revisions, addressing diseases with historically limited treatment access. 8. Maternal, Newborn, and Child Health Medicines Aligned with WHO guidance on essential medicines for children, covering treatment needs specific to pediatric patients. Why the KEML Matters for Exporters ✔ Signals public procurement priority Products aligned with KEML categories can help exporters identify therapeutic areas relevant to Kenya’s public-sector procurement and healthcare supply planning. ✔ Guides product portfolio decisions Exporters can use the KEML’s 35 therapeutic groups to identify where their existing catalog aligns — or has gaps — relative to Kenyan demand. ✔ Antibiotic classification matters for positioning Given the KEML’s AWaRe-based antibiotic classification, exporters supplying antimicrobials should understand where their products fall within that framework when engaging Kenyan buyers. ✔ Distinct from, but complementary to, PPB registration Inclusion in the KEML does not replace the applicable PPB registration and regulatory requirements for pharmaceutical products entering Kenya. How Exporters Can Use This Information ✔ Map your product portfolio against the KEML’s 35 therapeutic groups to spot supply opportunities ✔ Prioritize PPB registration for products in high-priority KEML categories, particularly NCD and neglected tropical disease medicines given their recent expansion ✔ Understand your antibiotic products’ AWaRe classification before engaging institutional buyers ✔ Track KEML revision cycles, since the list is reviewed periodically and category priorities shift accordingly Conclusion The Kenya Essential Medicines List offers a clear window into what Kenya’s healthcare system — increasingly shaped by its Universal Health Coverage agenda — actually needs and procures. Exporters who align product strategy with KEML priorities, on top of securing PPB registration, are better positioned for the county and national tender channels that drive a large share of Kenyan pharmaceutical demand. Partnering with an experienced pharma export company in India familiar with both PPB requirements and KEML priorities helps align product strategy with actual market demand rather than guesswork.